Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with chemotherapy for locally advanced malignant pleural mesothelioma
NCT04713761Phase 2Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in malignant pleural mesothelioma (MPM), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Major Pathologic Response up to 4 months, Health Related Quality of Life up to 6 months and 1 more. Status: unknown.
02
Drugs
toripalimab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04713761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713761.